The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Laps to laptops: Formula One sells its big data know-how

Thu, 24th Oct 2013 20:57

By Jeremy Wagstaff

SINGAPORE, Oct 25 (Reuters) - Wander around the pits at aFormula One car race and you're as likely to bump into alaptop-wielding scientist or engineer as a mechanic with aspanner.

And the lessons they are drawing from sensors on F1 tracks,cars and drivers are finding their way into a surprising rangeof industries - from drilling oil wells to making toothpaste.

"By chance or whatever we've ended up that F1 is a verystrong metaphor for how the world is developing around a moreindustrialised Internet," says Peter van Manen, managingdirector of McLaren Electronic Systems, part of a group whichmakes F1 cars. "You take information and you measure things, andfrom that you try to adapt how things behave and flow, so youcan make performance better."

Formula One racing, born after World War II, has longembraced rapid innovation. It can take seven years to get anordinary car from the drawing board to the showroom: An F1 carmay take just five months ... and have new components added toit each race weekend.

"There are very few industries which have a similar abilityto evolve at such pace and bring components or products tomarket at such speed," says Gerard Spensley, AT&T's globalaccounts director for F1.

But in recent years safety concerns and fears it wouldbankrupt itself have forced the sport to adopt tighterregulations, reducing speeds and spending. This has shiftedemphasis from hardware upgrades to real-time tweaks inefficiency and tactics to prise an extra millisecond or two fromcar and driver.

To do that, teams capture gigabytes of data from more than100 sensors on each F1 car, transmitting it back to the pit ordirect to their UK headquarters over high-speed cables. Onceengineers have analysed the data they feed advice back to thedriver - often within minutes or even seconds.

At last year's Brazilian Grand Prix, for example, theInfiniti Red Bull Racing team's UK factory used AT&T's highbandwidth link to assess the impact of an early collision ondriver Sebastian Vettel's car in time to send instructions totrackside engineers ahead of the first pit stop. That gave themtime, AT&T's Spensley said, to make alterations that helpedreduce the risk of further damage to the car. Vettel finishedsixth, retaining his title.

It's this pressure-cooker data analytics which some F1companies say offers an edge not only to racing motor cars butto other industries grappling with big data. The appeal lies inhow F1 teams tackle grabbing information on the fly, figuringout what's important and then converting that quickly into astrategy.

COMPLEXITY

Leading the charge is McLaren, a racing car company foundedin 1963 and now half-owned by Bahrain Mumtalakat Holding Co. Itsapplied technologies unit last month set up its Asianheadquarters in Singapore.

McLaren, for example, has used its experience grabbing datafrom fast moving cars to help build a network of antennae,sensors and masts for San Francisco's Bay Area Rapid Transit(BART). The network is used to collect video surveillance of thecarriages, monitor usage and provide passengers with WiFi.

This is not, says McLaren's van Manen, as easy as it sounds.Data bounces off walls, arrives in the wrong order or drops outentirely. "The complexity is in the detail of dealing with boththe high volume of data and the imperfections in the world."

McLaren is now working on similar projects in Europe.

To be sure, F1 is a small industry and McLaren is beingdriven in part by circumstance to seek new markets. In 2012 thegroup made a pre-tax loss of 2.5 million pounds ($4.05 million).The global market for big data is expected to be worth $23.7billion by 2016, most of it driven by big players such as IBM, Cisco Systems Inc and EMC Corp,forecasts Credit Suisse.

BRAND APPEAL

Not all in the industry are convinced there's much mileagein exporting its expertise.

"There is relevance but our analysis of the marketplace isthat we're far better concentrating very strongly on automotiveand other forms of motor sports," says Paul Newsome of WilliamsF1, whose hybrid engine technology is being tested on buses.

And even those who partner with F1 acknowledge that part ofits appeal is the brand. Paul Marriott of SAP, whosereal-time data analytics product HANA is being road-tested byMcLaren, says the company also benefits from the glamorousassociation with F1. A McLaren car sits in the company'sSingapore office.

But the partnerships run deeper. McLaren is working withU.S.-based IO Data Centers LLC to make data centers moreefficient by modelling likely demand.

"Every plane and car is now driven by software, constantlyadjusting every variable. Taking that thinking and applying itto the data center - where every input is constantly monitoredand controlled - was how the partnership was spun with McLaren,"IO's chief innovation officer Kevin Malik said in an interviewat the company's new Singapore data center.

The way McLaren uses predictive analytics to figure out thebest time to call a racing car in for a pit-stop is helpingBritain's airport controllers anticipate which planes shouldland on what runway. The software is currently being deployed atLondon's Heathrow Airport, according to McLaren.

McLaren is also working with an oil and gas company tofigure out the optimal path to drill through a honeycomb ofwells 10 miles underground. The solution, says McLaren's GeoffMcGrath, is a strategy straight out of racing: measure thecondition of the car, mine the models using historical data andthen advise a course of action - which will change all the timeas new events occur.

MANUFACTURING PIT STOPS

No action is too mundane for F1 to capture and analyse.Teams of mechanics practice changing wheels and tyres dozens oftimes a day, each session captured by video monitors and thenstudied for lessons.

This caught the eye of GlaxoSmithKline Plc, whichasked McLaren to help reduce the time spent switching itstoothpaste production lines. By standardizing materials, makingthe machines easier to handle and reviewing teams' performanceafter every batch, they cut the changeovers from 39 minutes to15.

"Changeovers in the manufacturing world are very like pitstops in an F1 team," says GSK's global manufacturing and supplychief, Roger Connor.

That said, the success of F1 teams in marketing theirexpertise to other industries may have less to do with theircutting edge innovation, than with their high profile work.

"It isn't so much the technology and methods that aredriving, but that these cases are so interesting that people arestarting to pay attention to things like sensors in thevehicle," says Craig Stires, a Singapore-based analyst with IDC."It creates that interest that radiates into other industries."

Whatever the reason, F1's innovation is causing ripples.Providing high-speed connectivity to F1, for example, has helpedcompanies like AT&T and Tata Communications theirservices overall.

Normally, setting up a network for a client would take 10weeks, Tata Communications chief marketing officer JulieWoods-Moss. F1 needs to have it done in three days. "So there'sbeen huge process innovations in the company that now we'restarting to see feeding to mainstream customers."

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.